Skip to main content
Sign In

Daniel Pollyea, MD, MS

Daniel Pollyea, MD
Daniel Pollyea, MD, MS
University of Colorado School of Medicine
  • Clinical Director of Leukemia Services
  • Associate Professor of Medicine


Contact information

Anschutz Medical Campus
1665 Aurora Court, MS F754
Aurora, CO  80045

Dr. Pollyea received his MD degree from the University of Chicago Pritzker School of Medicine. He stayed at the University of Chicago Hospital for his residency in Internal Medicine and served as Chief Medical Resident at Cook County Hospital. He then completed his fellowship training in Hematology and Oncology at Stanford University, where he also completed a Masters degree in Epidemiology with an emphasis on biostatistics and clinical trial design. In 2011 he came to the University of Colorado where he is currently the Clinical Director of Leukemia Services.

Dr. Pollyea has served as the Principal Investigator of multiple early-phase clinical trials, and has received funding for his work from the American Society of Hematology, the American Society of Clinical Oncology and the Leukemia and Lymphoma Society.
  • Indiana University, BS, 1999 
  • University of Chicago, MD, 2003
  • Stanford University, MS, 2011
Dr. Pollyea’s research interests involve developmental therapeutics for leukemia and other blood cancers through collaborative laboratory-based efforts and clinical trials involving novel therapies that he designs and leads. He is interested in developing drugs that target leukemia stem cells that will allow for definitive and curative therapies.

He is also focused on determining the mechanism of action of novel therapies, and determining whether biomarkers that predict responses can be identified. His research has applications for acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and myeloproliferative neoplasms (including chronic myeloid leukemia) as well as chronic lymphocytic leukemia.
1. Ravandi F, Erba HP, Pollyea DA. Expert insights into the comtemporary management of older adults with acute myeloid leukemia. Cancer Control. 2013 Oct;20(4 Suppl):5-16.

2. Narayanan V, Gutman JA, Pollyea DA, Jimeno A. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. Drugs Today. 2013 Jul;49(7):447-56.

3. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. New England Journal of Medicine. 2013 May 9;368(19):1781-90.

4. Narayanan V, Pollyea DA, Gutman JA, Jimeno A. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Drugs Today (Barc). 2013 Apr;49(4):261-9.

5. Coffey DG, Pollyea DA, Myint H, Smith C, Gutman JA. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index. Bone Marrow Transplant. 2013 Mar 18. [Epub ahead of print]

6. Pollyea DA, Zehnder J, Coutre S, Gotlib J, Gallegos L, Abdel-Wahab O, Greenberg P, Zhang B, Liedtke M, Berube C, Levine R, Mitchell BS, Medeiros BC. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica. 2013 Apr;98(4):591-6.

7. Pollyea DA, Kohrt HE, Zhang B, Zehnder J, Schenkein D, Fantin V, Straley K, Vasanthakumar A, Abdel-Wahab O, Levine R, Godley LA, Medeiros BC. 2-Hydroxyglutarate in IDH Mutant AML: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels. Leuk Lymphoma. 2013 Feb;54(2):408-10.

8. Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, Bhattacharya S, Zehnder J, Liedtke M, Gotlib JR, Coutre S, Berube C, Melnick A, Levine R, Mitchell BS, Medeiros BC.  Safety, Efficacy and Biological Predictors of Response to Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia. Leukemia. 2012 May;26(5):893-901.

9. Pollyea DA, Raval A, Kusler B, Gotlib JR, Alizadeh AA, Mitchell BS. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematological Oncology. 2011 Sep;29(3):157-60.

10. Huang M, Whang P, Chodaparambil JV, Pollyea DA, Kusler B, Xu L, Felsher DW, Mitchell BS. Reactive oxygen species regulate nucleostemin oligomerization and protein degradation.  Journal of Biological Chemistry. 2011 Apr 1;286(13):11035-46.

11. Pollyea DA, Kohrt HE, Medeiros BC. Acute Myeloid Leukemia in the Elderly: A Review. British Journal of Haematology. 2011 Mar; 152(5):524-42.

12. Kohrt H, Patel P, Ho M, Owen T, Pollyea D, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh A, and Medeiros B. Second line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. American Journal of Hematology. 2010 Nov;85(11):877-81.

13. Pollyea DA, Brown J, Horning SJ.  The utility of influenza vaccination for oncology patients.  Journal of Clinical Oncology. 2010 May 10;28(14):2481-90.

14. Pollyea DA, George TI, Corless C, Gotlib J.  When yellow jackets attack: Recurrent and severe anaphylactic reactions to insect bites and stings.  American Journal of Hematology. 2009 Dec;84(12):843-6.

15. Pollyea DA, Artz A, Stock W, Daugherty C, Godley L, Odenike O, Rich E, Smith S, Zimmerman T, Zhang Y, Huo D, Larson R, Van Besien K.  Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.  Bone Marrow Transplant. 2007 Dec;40(11):1027-32.

16. Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Cerro PD, van Besien K.  Chimerism does not predict for outcome after alemtuzumab based conditioning.  Bone Marrow Transplant. 2007 Jul;40(2):181.

17. Artz A, Pollyea D, Kocherginsky M, Daugherty C, Zimmerman T, Smith S, Godley L, Thirman M, Rich E, Larson R, Stock W, Balducci L, Van Besien K.  Performance status and comorbidity determine transplant related mortality after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplant. 2006 Sep;12(9):954-64..

18. Kline J, Pollyea DA, Stock W, Artz A, Rich E, Godley L, Zimmerman T, Thompson K, Pursell K, Larson RA, van Besien K.  Pre-transplant Ganciclovir and post-transplant high-dose valacyclovir reduce CMV infections after alemtuzumab based conditioning.  Bone Marrow Transplant 2006;3:307-10. 

19. Huang J, Frischer JS, New T, Kim EG, Serur A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ.  TNP-470 promotes initial vascular sprouting in xenograft tumors. Molecular Cancer Therapeutics, 2004;3(3):335-343.